The Quantellect read.As of Nov 19, 2026, 8 active firms cover Ascentage Pharma Group International: 8 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $33.00 to $51.00, a moderate spread. The average target of $43.29 sits 233% above the current $13.01. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 5 to 8 over recent months. On the fundamentals, the Street sees revenue growth near 51% this year and 71% next, consensus EPS building from about $-0.51 next quarter toward $-0.65 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 active firms
Buy
Strong Buy00%
Buy8100%
Neutral00%
Sell00%
Strong Sell00%
Based on 8 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$43.29
+232.6% upside
Average target across 7 active firms as of Nov 19, 2026 vs $13.01 current
Highest Target$51.00
Average Target$43.29
Lowest Target$33.00
Detailed analyst forecasts for AAPG
Showing 1–8 of 8 named analysts shown · 8 active firms in the rating projection
As of Nov 19, 2026, 8 of 8 active firms rate AAPG a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
AAPG EPS & revenue forecast
EPS · NEXT QUARTER
$-0.51
Range $-0.51 – $-0.50 · 2 analysts
Next period, 2 analysts expect Ascentage Pharma Group International to earn $-0.51 a share (range $-0.51 – $-0.50), versus — a year earlier. Full-year consensus is $-1.18, growing to $-0.65 the year after.
REVENUE · NEXT QUARTER
$199.4M
Range $164.6M – $234.2M · 2 analysts
Revenue is expected to reach $199.4M (range $164.6M – $234.2M). Full-year consensus is $676.9M, rising to $1.4B next year.
Top analysts covering Ascentage Pharma Group International
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on AAPG.
#1
Mayank Mamtani
B. Riley Securities · Rank #36
Buy
$45.00+245.8% to target
Overall win rate
49%
+ Follow
#2
Brian Cheng
JP Morgan · Rank #87
Buy
$33.00+153.6% to target
Overall win rate
51%
+ Follow
#3
Jeff Jones
Oppenheimer · Rank #320
Buy
$45.00+245.8% to target
Overall win rate
32%
+ Follow
#4
Yigal Nochomovitz
Citigroup · Rank #381
Buy
$46.00+253.5% to target
Overall win rate
38%
+ Follow
#5
Justin Zelin
BTIG · Rank #495
Buy
$50.00+284.2% to target
Overall win rate
30%
+ Follow
AAPG stock forecast FAQ
What is AAPG's average 12-month price target?+
The 7 active firms with a live target average $43.29 for Ascentage Pharma Group International over the next 12 months, ranging from a $51.00 high to a $33.00 low, as of Nov 19, 2026.
Is AAPG stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 8 active firms as of Nov 19, 2026, 8 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for AAPG?+
The Street-high target is $51.00 (Truist Securities), and the Street-low is $33.00 (JP Morgan). The average of all 7 active-firm targets is $43.29.
How many active Wall Street firms cover AAPG?+
8 active firms have a recognized rating on Ascentage Pharma Group International as of Nov 19, 2026, and 7 active firms carry a live 12-month price target.
Who is the most accurate analyst covering AAPG?+
Among analysts who currently cover AAPG, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #36). Their current call is Buy with a $45.00 target.
What is Ascentage Pharma Group International's projected EPS for next quarter?+
The consensus estimate is $-0.51 per share (range $-0.51 – $-0.50) across 2 analysts. Full-year EPS is projected at $-1.18, rising to $-0.65 the following year.
How much revenue is Ascentage Pharma Group International expected to report next quarter?+
Consensus revenue is $199.4M (range $164.6M – $234.2M). Full-year revenue is projected at $676.9M, growing to $1.4B next year.
Have analysts been upgrading or downgrading AAPG lately?+
As of Nov 19, 2026, 8 of 8 active firms rate AAPG a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their AAPG calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.